GGrantIndex
← Leaderboards

Richard M. Silver

Medical University Of South Carolina

Google Scholar ↗PubMed ↗ORCID ↗
$2,926,564
Attributed
$3,355,475
Total exposure
16
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY2005–24
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$9,335,328 · 17

By mechanism

P60$7,679,821 · 5
R41$857,823 · 3
U01$390,896 · 1
R21$326,502 · 1
M01$80,286 · 7

Top collaborators

Most similar at Medical University Of South Carolina

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchSystemic SclerodermaHuman SubjectInterstitial Lung DiseasesHuman Therapy EvaluationFibroblastsDrug Screening /EvaluationSclerodermaRheumatismClinical TrialsLungAfrican AmericanSkinInflammationProteinsSuccessLung DiseasesExtracellular Matrix ProteinsExhibitsMet GeneMorbidity - Disease RateDermalEventLead

Grant awards (35)

Development of a Novel Therapeutic Agent for Skin Fibrosis$306,518
R41 · FY2024 · AR
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis$299,295
R41 · FY2023 · HL
Preclinical Development of M10 as a Therapeutic Agent for Scleroderma$252,010
R41 · FY2021 · AR · contact PI
Defective c-MET signaling in African American scleroderma patients$316,194
P60 · FY2016 · AR · contact PI
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma$151,365
R21 · FY2016 · AR · contact PI
Defective c-MET signaling in African American scleroderma patients$299,592
P60 · FY2015 · AR · contact PI
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma$175,137
R21 · FY2015 · AR · contact PI
Defective c-MET signaling in African American scleroderma patients$299,596
P60 · FY2014 · AR · contact PI
Defective c-MET signaling in African American scleroderma patients$298,654
P60 · FY2013 · AR · contact PI
Defective c-MET signaling in African American scleroderma patients$316,011
P60 · FY2012 · AR · contact PI
CLINICAL TRIAL: APPLE STUDY$6,588
M01 · FY2008 · RR · contact PI
NIAMS Clinical Research Center for Rheumatoid Disease$1,134,702
P60 · FY2007 · AR · contact PI
Administrative Core$169,921
P60 · FY2007 · AR · contact PI
APPLE STUDY$10,111
M01 · FY2007 · RR · contact PI
NIAMS Clinical Research Center for Rheumatoid Disease$1,171,624
P60 · FY2006 · AR · contact PI
NIAMS Clinical Research Center for Rheumatoid Disease$1,188,665
P60 · FY2005 · AR
CYCLOPHOSPHAMIDE VS PLACEBO IN SYST SCL PULM ALVEOLITIS$14,090
M01 · FY2005 · RR
NIAMS Clinical Research Center for Rheumatoid Disease$9,588
P60 · FY2005 · AR
APPLE STUDY$4,901
M01 · FY2005 · RR
NUMBER OF SUBJECTS BAL STUDIES (PATIENTS AND CONTROLS): 112$0
P60 · FY2005 · AR
Number of Subjects Skin Biopsies (Patients and Controls): 120$0
P60 · FY2005 · AR
NIAMS Clinical Research Center for Rheumatoid Disease$1,177,770
P60 · FY2004 · AR
NIAMS Clinical Research Center for Rheumatoid Disease$67,102
P60 · FY2004 · AR
Cyclophosphamide vs. Placebo in Syst. Scl. Pulm. Alveolitis$27,155
M01 · FY2004 · RR
NIAMS Clinical Research Center for Rheumatoid Disease$16,775
P60 · FY2004 · AR
NIAMS Clinical Research Center for Rheumatoid Disease$1,213,627
P60 · FY2003 · AR
SCLERODERMA LUNG STUDY$1
U01 · FY2003 · HL
SCLERODERMA LUNG STUDY$124,498
U01 · FY2002 · HL
TRIAL OF BAY 12-9566 IN OSTEOARTHRITIS (OA) OF KNEES$0
M01 · FY2002 · RR
SCLERODERMA LUNG STUDY$142,016
U01 · FY2001 · HL
TRIAL OF BAY 12-9566 IN OSTEOARTHRITIS (OA) OF KNEES$0
M01 · FY2001 · RR
TRIAL OF BAY 12-9566 IN OSTEOARTHRITIS (OA) OF KNEES$0
M01 · FY2001 · RR
TRIAL OF BAY 12-9566 IN OSTEOARTHRITIS (OA) OF KNEES$0
M01 · FY2001 · RR
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$124,381
U01 · FY2000 · HL
BRONCHOALVEOLAR LAVAGE IN CONNECTIVE TISSUE DISEASE$17,441
M01 · FY2000 · RR